Logotipo del repositorio
Logotipo del repositorio
 

Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2eng
dc.contributor.authorCano, Raquel
dc.contributor.authorPérez, José L.
dc.contributor.authorAngarita Dávila, Lissé
dc.contributor.authorOrtega, Ángel
dc.contributor.authorGómez, Yosselin
dc.contributor.authorValero-Cedeño, Nereida Josefina
dc.contributor.authorParra, Heliana
dc.contributor.authorManzano, Alexander
dc.contributor.authorVéliz Castro, Teresa Isabelspa
dc.contributor.authorDíaz Albornoz, María P
dc.contributor.authorCano, Gabriel
dc.contributor.authorRojas-Quintero, Joselyn
dc.contributor.authorChacín, Maricarmen
dc.contributor.authorBermúdez, Valmore
dc.date.accessioned2021-09-13T23:36:01Z
dc.date.available2021-09-13T23:36:01Z
dc.date.issued2021
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is considered the most common liver disorder, affecting around 25% of the population worldwide. It is a complex disease spectrum, closely linked with other conditions such as obesity, insulin resistance, type 2 diabetes mellitus, and metabolic syndrome, which may increase liver-related mortality. In light of this, numerous efforts have been carried out in recent years in order to clarify its pathogenesis and create new prevention strategies. Currently, the essential role of environmental pollutants in NAFLD development is recognized. Particularly, endocrine-disrupting chemicals (EDCs) have a notable influence. EDCs can be classified as natural (phytoestrogens, genistein, and coumestrol) or synthetic, and the latter ones can be further subdivided into industrial (dioxins, polychlorinated biphenyls, and alkylphenols), agricultural (pesticides, insecticides, herbicides, and fungicides), residential (phthalates, polybrominated biphenyls, and bisphenol A), and pharmaceutical (parabens). Several experimental models have proposed a mechanism involving this group of substances with the disruption of hepatic metabolism, which promotes NAFLD. These include an imbalance between lipid influx/efflux in the liver, mitochondrial dysfunction, liver inflammation, and epigenetic reprogramming. It can be concluded that exposure to EDCs might play a crucial role in NAFLD initiation and evolution. However, further investigations supporting these effects in humans are required.eng
dc.format.mimetypepdfspa
dc.identifier.citationCano, R., Pérez, J., Dávila, L., Ortega, Á., Gómez, Y., Valero-Cedeño, N., Parra, H., et al. (2021). Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. International Journal of Molecular Sciences, 22(9), 4807. MDPI AG. Retrieved from http://dx.doi.org/10.3390/ijms22094807eng
dc.identifier.doihttps://doi.org/10.3390/ijms22094807
dc.identifier.issn14220067
dc.identifier.urihttps://hdl.handle.net/20.500.12442/8361
dc.language.isoengeng
dc.publisherMDPIeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceInternational Journal of Molecular Scienceseng
dc.sourceVol. 22 N° 9 (2021)
dc.subjectNon-alcoholic fatty liver diseaseeng
dc.subjectEndocrine-disrupting chemicalseng
dc.subjectLiver disordereng
dc.subjectEnvironmental pollutantseng
dc.subjectExposureeng
dc.titleRole of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Revieweng
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesChalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [CrossRef]eng
dcterms.referencesAmini, M.; Ansari, I.; Yekesadat, S.; Vaseie, M.; Malekhoseyni, M. Response rate to the vaccination with hepatitis b vaccine among cardiovascular health staff in Tehran. Latinoam. Hipertens. 2020, 14, 562–567.eng
dcterms.referencesYounossi, Z.; Tacke, F.; Arrese, M.; Chander Sharma, B.; Mostafa, I.; Bugianesi, E.; Wai-Sun Wong, V.; Yilmaz, Y.; George, J.; Fan, J.; et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Hepatology. Hepatology 2019, 69, 2672–2682. [CrossRef] [PubMed]eng
dcterms.referencesBermudez, V.; Moisés, R.; Lisney, V.; Yettana, L.; Ana, C.; ali, U.; Guerra-Torres, X.; Colmenares, C.A.; Chacín, M.; Rojas Quintero, J.; et al. Pharmacologic Treatment of Obesity: Pitfalls and New Promises. Rev. Latinoam. Hipertens. 2008, 5, 137–147eng
dcterms.referencesYounossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 11–20. [CrossRef]eng
dcterms.referencesYounossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology 2016, 64, 73–84. [CrossRef] [PubMed]eng
dcterms.referencesFang, Y.-L.; Chen, H.; Wang, C.-L.; Liang, L. Pathogenesis of Non-Alcoholic Fatty Liver Disease in Children and Adolescence: From “Two Hit Theory” to “Multiple Hit Model”. World J. Gastroenterol. 2018, 24, 2974–2983. [CrossRef]eng
dcterms.referencesCarr, R.M.; Oranu, A.; Khungar, V. Nonalcoholic Fatty Liver Disease. Gastroenterol. Clin. N. Am. 2016, 45, 639–652. [CrossRef]eng
dcterms.referencesSouki-Rincón, A.; Sandoval, M.; Sánchez, G.; Andrade, U.; García-Rondón, D.; Cano-Ponce, C.; Medina, M.; Almarza, J.; Urdaneta, Y.; González, C. Intake of saturated fatty acids and insulin sensitivity in obese young adults from Maracaibo. Rev. Latinoam. Hipertens. 2008, 3, 159–165eng
dcterms.referencesPetta, S.; Gastaldelli, A.; Rebelos, E.; Bugianesi, E.; Messa, P.; Miele, L.; Svegliati-Baroni, G.; Valenti, L.; Bonino, F. Pathophysiology of Non Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2016, 17, 2082. [CrossRef]eng
dcterms.referencesMasarone, M.; Rosato, V.; Dallio, M.; Gravina, A.G.; Aglitti, A.; Loguercio, C.; Federico, A.; Persico, M. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid. Med. Cell. Longev. 2018, 2018, 1–14. [CrossRef]eng
dcterms.referencesArciello, M.; Gori, M.; Maggio, R.; Barbaro, B.; Tarocchi, M.; Galli, A.; Balsano, C. Environmental Pollution: A Tangible Risk for NAFLD Pathogenesis. Int. J. Mol. Sci. 2013, 14, 22052–22066. [CrossRef]eng
dcterms.referencesPapalou, O.; Kandaraki, E.A.; Papadakis, G.; Diamanti-Kandarakis, E. Endocrine Disrupting Chemicals: An Occult Mediator of Metabolic Disease. Front. Endocrinol. 2019, 10, 112. [CrossRef]eng
dcterms.referencesBergman, Å.; Heindel, J.J.; Kasten, T.; Kidd, K.A.; Jobling, S.; Neira, M.; Zoeller, R.T.; Becher, G.; Bjerregaard, P.; Bornman, R.; et al. The Impact of Endocrine Disruption: A Consensus Statement on the State of the Science. Environ. Health Perspect. 2013, 121, A104–A106. [CrossRef]eng
dcterms.referencesVoPham, T. Environmental Risk Factors for Liver Cancer and Nonalcoholic Fatty Liver Disease. Curr. Epidemiol. Rep. 2019, 6, 50–66. [CrossRef] [PubMed]eng
dcterms.referencesKlaunig, J.E.; Li, X.; Wang, Z. Role of Xenobiotics in the Induction and Progression of Fatty Liver Disease. Toxicol. Res. 2018, 7, 664–680. [CrossRef] [PubMed]eng
dcterms.referencesWei, J.; Sun, X.; Chen, Y.; Li, Y.; Song, L.; Zhou, Z.; Xu, B.; Lin, Y.; Xu, S. Perinatal Exposure to Bisphenol A Exacerbates Nonalcoholic Steatohepatitis-like Phenotype in Male Rat Offspring Fed on a High-Fat Diet. J. Endocrinol. 2014, 222, 313–325. [CrossRef] [PubMed]eng
dcterms.referencesMarty, M.S.; Carney, E.W.; Rowlands, J.C. Endocrine Disruption: Historical Perspectives and Its Impact on the Future of Toxicology Testing. Toxicol. Sci. Off. J. Soc. Toxicol. 2011, 120 (Suppl. 1), S93–S108. [CrossRef] [PubMed]eng
dcterms.referencesDarbre, P.D. The History of Endocrine-Disrupting Chemicals. Curr. Opin. Endocr. Metab. Res. 2019, 7, 26–33. [CrossRef]eng
dcterms.referencesLee, D.H. Evidence of the Possible Harm of Endocrine-Disrupting Chemicals in Humans: Ongoing Debates and Key Issues. Endocrinol. Metab. Seoul Korea 2018, 33, 44–52. [CrossRef] [PubMed]eng
dcterms.referencesCommittee, E.S. Scientific Opinion on the Hazard Assessment of Endocrine Disruptors: Scientific Criteria for Identification of Endocrine Disruptors and Appropriateness of Existing Test Methods for Assessing Effects Mediated by These Substances on Human Health and the Environment. EFSA J. 2013, 11, 3132. [CrossRef]eng
dcterms.referencesSlama, R.; Bourguignon, J.-P.; Demeneix, B.; Ivell, R.; Panzica, G.; Kortenkamp, A.; Zoeller, R.T. Scientific Issues Relevant to Setting Regulatory Criteria to Identify Endocrine-Disrupting Substances in the European Union. Environ. Health Perspect. 2016, 124, 1497–1503. [CrossRef]eng
dcterms.referencesZoeller, R.T.; Brown, T.R.; Doan, L.L.; Gore, A.C.; Skakkebaek, N.E.; Soto, A.M.; Woodruff, T.J.; Vom Saal, F.S. EndocrineDisrupting Chemicals and Public Health Protection: A Statement of Principles from The Endocrine Society. Endocrinology 2012, 153, 4097–4110. [CrossRef] [PubMed]eng
dcterms.referencesGore, A.C.; Chappell, V.A.; Fenton, S.E.; Flaws, J.A.; Nadal, A.; Prins, G.S.; Toppari, J.; Zoeller, R.T. Executive Summary to EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr. Rev. 2015, 36, 593–602. [CrossRef]eng
dcterms.referencesYang, O.; Kim, H.L.; Weon, J.-I.; Seo, Y.R. Endocrine-Disrupting Chemicals: Review of Toxicological Mechanisms Using Molecular Pathway Analysis. J. Cancer Prev. 2015, 20, 12–24. [CrossRef] [PubMed]eng
dcterms.referencesFrye, C.; Bo, E.; Calamandrei, G.; Calzà, L.; Dessì-Fulgheri, F.; Fernández, M.; Fusani, L.; Kah, O.; Kajta, M.; Le Page, Y.; et al. Endocrine Disrupters: A Review of Some Sources, Effects, and Mechanisms of Actions on Behaviour and Neuroendocrine Systems: EDCs-Sources, Effects & Mechanisms. J. Neuroendocrinol. 2012, 24, 144–159. [CrossRef]eng
dcterms.referencesBarouki, R. Endocrine Disruptors: Revisiting Concepts and Dogma in Toxicology. Comptes Rendus Biol. 2017, 340, 410–413. [CrossRef] [PubMed]eng
dcterms.referencesYilmaz, B.; Terekeci, H.; Sandal, S.; Kelestimur, F. Endocrine Disrupting Chemicals: Exposure, Effects on Human Health, Mechanism of Action, Models for Testing and Strategies for Prevention. Rev. Endocr. Metab. Disord. 2020, 21, 127–147. [CrossRef]eng
dcterms.referencesDiamanti-Kandarakis, E.; Palioura, E.; Kandarakis, S.A.; Koutsilieris, M. The Impact of Endocrine Disruptors on Endocrine Targets. Horm. Metab. Res. 2010, 42, 543–552. [CrossRef] [PubMed]eng
dcterms.referencesSargis, R.M.; Heindel, J.J.; Padmanabhan, V. Interventions to Address Environmental Metabolism-Disrupting Chemicals: Changing the Narrative to Empower Action to Restore Metabolic Health. Front. Endocrinol. 2019, 10, 33. [CrossRef] [PubMed]eng
dcterms.referencesKabir, E.R.; Rahman, M.S.; Rahman, I. A Review on Endocrine Disruptors and Their Possible Impacts on Human Health. Environ. Toxicol. Pharmacol. 2015, 40, 241–258. [CrossRef]eng
dcterms.referencesDiamanti-Kandarakis, E.; Bourguignon, J.-P.; Giudice, L.C.; Hauser, R.; Prins, G.S.; Soto, A.M.; Zoeller, R.T.; Gore, A.C. EndocrineDisrupting Chemicals: An Endocrine Society Scientific Statement. Endocr. Rev. 2009, 30, 293–342. [CrossRef] [PubMed]eng
dcterms.referencesLauretta, R.; Sansone, A.; Sansone, M.; Romanelli, F.; Appetecchia, M. Endocrine Disrupting Chemicals: Effects on Endocrine Glands. Front. Endocrinol. 2019, 10, 178. [CrossRef] [PubMed]eng
dcterms.referencesJalal, N.; Surendranath, A.R.; Pathak, J.L.; Yu, S.; Chung, C.Y. Bisphenol A (BPA) the Mighty and the Mutagenic. Toxicol. Rep. 2018, 5, 76–84. [CrossRef] [PubMed]eng
dcterms.referencesRudel, R.A.; Gray, J.M.; Engel, C.L.; Rawsthorne, T.W.; Dodson, R.E.; Ackerman, J.M.; Rizzo, J.; Nudelman, J.L.; Brody, J.G. Food Packaging and Bisphenol A and Bis(2-Ethyhexyl) Phthalate Exposure: Findings from a Dietary Intervention. Environ. Health Perspect. 2011, 119, 914–920. [CrossRef] [PubMed]eng
dcterms.referencesChen, Y.; Li, C.; Song, P.; Yan, B.; Yang, X.; Wu, Y.; Ma, P. Hepatic and Renal Tissue Damage in Balb/c Mice Exposed to Diisodecyl Phthalate: The Role of Oxidative Stress Pathways. Food Chem. Toxicol. 2019, 132, 110600. [CrossRef] [PubMed]eng
dcterms.referencesWang, C.; Yang, L.; Wang, S.; Zhang, Z.; Yu, Y.; Wang, M.; Cromie, M.; Gao, W.; Wang, S.-L. The Classic EDCs, Phthalate Esters and Organochlorines, in Relation to Abnormal Sperm Quality: A Systematic Review with Meta-Analysis. Sci. Rep. 2016, 6, 19982. [CrossRef]eng
dcterms.referencesQin, W.; Deng, T.; Cui, H.; Zhang, Q.; Liu, X.; Yang, X.; Chen, M. Exposure to Diisodecyl Phthalate Exacerbated Th2 and Th17-Mediated Asthma through Aggravating Oxidative Stress and the Activation of P38 MAPK. Food Chem. Toxicol. 2018, 114, 78–87. [CrossRef] [PubMed]eng
dcterms.referencesAmaro, A.A.; Esposito, A.I.; Mirisola, V.; Mehilli, A.; Rosano, C.; Noonan, D.M.; Albini, A.; Pfeffer, U.; Angelini, G. Endocrine Disruptor Agent Nonyl Phenol Exerts An Estrogen-like Transcriptional Activity on Estrogen Receptor Positive Breast Cancer Cells. Curr. Med. Chem. 2014, 21, 630–640. [CrossRef]eng
dcterms.referencesKazemi, S.; Mousavi Kani, S.N.; Ghasemi-Kasman, M.; Aghapour, F.; Khorasani, H.; Moghadamnia, A.A. Nonylphenol Induces Liver Toxicity and Oxidative Stress in Rat. Biochem. Biophys. Res. Commun. 2016, 479, 17–21. [CrossRef]eng
dcterms.referencesMonneret, C. What Is an Endocrine Disruptor? Comptes Rendus Biol. 2017, 340, 403–405. [CrossRef]eng
dcterms.referencesBonefeld-Jørgensen, E.C.; Ghisari, M.; Wielsøe, M.; Bjerregaard-Olesen, C.; Kjeldsen, L.S.; Long, M. Biomonitoring and HormoneDisrupting Effect Biomarkers of Persistent Organic Pollutants In Vitro and Ex Vivo. Basic Clin. Pharmacol. Toxicol. 2014, 115, 118–128. [CrossRef]eng
dcterms.referencesDeierlein, A.L.; Rock, S.; Park, S. Persistent Endocrine-Disrupting Chemicals and Fatty Liver Disease. Curr. Environ. Health Rep. 2017, 4, 439–449. [CrossRef]eng
dcterms.referencesHung, H.; Katsoyiannis, A.A.; Guardans, R. Ten Years of Global Monitoring under the Stockholm Convention on Persistent Organic Pollutants (POPs): Trends, Sources and Transport Modelling. Environ. Pollut. 2016, 217, 1–3. [CrossRef] [PubMed]eng
dcterms.referencesMagulova, K.; Priceputu, A. Global Monitoring Plan for Persistent Organic Pollutants (POPs) under the Stockholm Convention: Triggering, Streamlining and Catalyzing Global POPs Monitoring. Environ. Pollut. 2016, 217, 82–84. [CrossRef] [PubMed]eng
dcterms.referencesRahman, Z.; Singh, V.P. The Relative Impact of Toxic Heavy Metals (THMs) (Arsenic (As), Cadmium (Cd), Chromium (Cr)(VI), Mercury (Hg), and Lead (Pb)) on the Total Environment: An Overview. Environ. Monit. Assess. 2019, 191, 419. [CrossRef] [PubMed]eng
dcterms.referencesBarouki, R. Endocrine disruptor compounds and new mechanisms of toxicity networks. Rev. Prat. 2018, 68, 1069–1074.eng
dcterms.referencesSawada, N. Association between Arsenic Intake and Cancer—From the Viewpoint of Epidemiological Study. Nippon Eiseigaku Zasshi 2018, 73, 265–268. [CrossRef] [PubMed]eng
dcterms.referencesKim, K.-H.; Jahan, S.A.; Kabir, E.; Brown, R.J.C. A Review of Airborne Polycyclic Aromatic Hydrocarbons (PAHs) and Their Human Health Effects. Environ. Int. 2013, 60, 71–80. [CrossRef]eng
dcterms.referencesAlegbeleye, O.O.; Opeolu, B.O.; Jackson, V.A. Polycyclic Aromatic Hydrocarbons: A Critical Review of Environmental Occurrence and Bioremediation. Environ. Manag. 2017, 60, 758–783. [CrossRef]eng
dcterms.referencesLau, C. Perfluorinated Compounds. Exp. Suppl. 2012, 101, 47–86. [CrossRef]eng
dcterms.referencesChen, A.; Zhou, X.; Cheng, Y.; Tang, S.; Liu, M.; Wang, X. Design and Optimization of the Cocktail Assay for Rapid Assessment of the Activity of UGT Enzymes in Human and Rat Liver Microsomes. Toxicol. Lett. 2018, 295, 379–389. [CrossRef] [PubMed]eng
dcterms.referencesRowland, A.; Miners, J.O.; Mackenzie, P.I. The UDP-Glucuronosyltransferases: Their Role in Drug Metabolism and Detoxification. Int. J. Biochem. Cell Biol. 2013, 45, 1121–1132. [CrossRef] [PubMed]eng
dcterms.referencesBissig, K.-D.; Han, W.; Barzi, M.; Kovalchuk, N.; Ding, L.; Fan, X.; Pankowicz, F.P.; Zhang, Q.-Y.; Ding, X. P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity. Drug Metab. Dispos. 2018, 46, 1734–1744. [CrossRef] [PubMed]eng
dcterms.referencesMuncke, J. Exposure to Endocrine Disrupting Compounds via the Food Chain: Is Packaging a Relevant Source? Sci. Total Environ. 2009, 407, 4549–4559. [CrossRef]eng
dcterms.referencesGálvez-Ontiveros, Y.; Páez, S.; Monteagudo, C.; Rivas, A. Endocrine Disruptors in Food: Impact on Gut Microbiota and Metabolic Diseases. Nutrients 2020, 12, 1158. [CrossRef] [PubMed]eng
dcterms.referencesCano-Sancho, G.; Marchand, P.; Le Bizec, B.; Antignac, J.-P. The Challenging Use and Interpretation of Blood Biomarkers of Exposure Related to Lipophilic Endocrine Disrupting Chemicals in Environmental Health Studies. Mol. Cell. Endocrinol. 2020, 499, 110606. [CrossRef]eng
dcterms.referencesNishida, K.; Kobayashi, M.; Miyamoto, H.; Yoshikawa, N.; Fumoto, S.; Sasaki, H.; Nakamura, J. Relationship between Lipophilicity and Absorption from the Liver Surface of Paraben Derivatives and Antipyrine in Rats: Lipophilic Drug Absorption from Liver Surface. J. Pharm. Pharmacol. 2011, 63, 736–740. [CrossRef]eng
dcterms.referencesLonard, D.M.; O’malley, B.W. Nuclear Receptor Coregulators: Judges, Juries, and Executioners of Cellular Regulation. Mol. Cell 2007, 27, 691–700. [CrossRef]eng
dcterms.referencesCave, M.C.; Clair, H.B.; Hardesty, J.E.; Falkner, K.C.; Feng, W.; Clark, B.J.; Sidey, J.; Shi, H.; Aqel, B.A.; McClain, C.J.; et al. Nuclear Receptors and Nonalcoholic Fatty Liver Disease. Biochim. Biophys. Acta 2016, 1859, 1083–1099. [CrossRefeng
dcterms.referencesCruz-Hurtado, M.; de López-González, M.L.; Mondragón, V.; Sierra-Santoyo, A. In Vitro Phase I Metabolism of Vinclozolin by Human Liver Microsomes. Xenobiotica 2019, 49, 895–904. [CrossRef] [PubMed]eng
dcterms.referencesCarrão, D.B.; Habenchus, M.D.; de Albuquerque, N.C.P.; da Silva, R.M.; Lopes, N.P.; de Oliveira, A.R.M. In Vitro Inhibition of Human CYP2D6 by the Chiral Pesticide Fipronil and Its Metabolite Fipronil Sulfone: Prediction of Pesticide-Drug Interactions. Toxicol. Lett. 2019, 313, 196–204. [CrossRef] [PubMed]eng
dcterms.referencesSychev, D.; Ashraf, G.M.; Svistunov, A.; Maksimov, M.; Tarasov, V.; Chubarev, V.N.; Otdelenov, V.A.; Denisenko, N.P.; Barreto, G.E.; Aliev, G. The Cytochrome P450 Isoenzyme and Some New Opportunities for the Prediction of Negative Drug Interaction in Vivo. Drug Des. Devel. Ther. 2018, 12, 1147–1156. [CrossRef]eng
dcterms.referencesDocea, A.O.; Vassilopoulou, L.; Fragou, D.; Arsene, A.L.; Fenga, C.; Kovatsi, L.; Petrakis, D.; Rakitskii, V.N.; Nosyrev, A.E.; Izotov, B.N.; et al. CYP Polymorphisms and Pathological Conditions Related to Chronic Exposure to Organochlorine Pesticides. Toxicol. Rep. 2017, 4, 335–341. [CrossRef]eng
dcterms.referencesLee, P.C.; Chakraborty Patra, S.; Stelloh, C.T.; Lee, W.; Struve, M. Interaction of Nonylphenol and Hepatic CYP1A in Rats. Biochem. Pharmacol. 1996, 52, 885–889. [CrossRef]eng
dcterms.referencesAdemollo, N.; Patrolecco, L.; Rauseo, J.; Nielsen, J.; Corsolini, S. Bioaccumulation of Nonylphenols and Bisphenol A in the Greenland Shark Somniosus Microcephalus from the Greenland Seawaters. Microchem. J. 2018, 136, 106–112. [CrossRef]eng
dcterms.referencesLv, Y.-Z.; Yao, L.; Wang, L.; Liu, W.-R.; Zhao, J.-L.; He, L.-Y.; Ying, G.-G. Bioaccumulation, Metabolism, and Risk Assessment of Phenolic Endocrine Disrupting Chemicals in Specific Tissues of Wild Fish. Chemosphere 2019, 226, 607–615. [CrossRef] [PubMed]eng
dcterms.referencesBenjamin, S.; Masai, E.; Kamimura, N.; Takahashi, K.; Anderson, R.C.; Faisal, P.A. Phthalates Impact Human Health: Epidemiological Evidences and Plausible Mechanism of Action. J. Hazard. Mater. 2017, 340, 360–383. [CrossRef] [PubMed]eng
dcterms.referencesPraveena, S.M.; Teh, S.W.; Rajendran, R.K.; Kannan, N.; Lin, C.-C.; Abdullah, R.; Kumar, S. Recent Updates on Phthalate Exposure and Human Health: A Special Focus on Liver Toxicity and Stem Cell Regeneration. Environ. Sci. Pollut. Res. 2018, 25, 11333–11342. [CrossRef]eng
dcterms.referencesLarsson, K.; Ljung Björklund, K.; Palm, B.; Wennberg, M.; Kaj, L.; Lindh, C.H.; Jönsson, B.A.G.; Berglund, M. Exposure Determinants of Phthalates, Parabens, Bisphenol A and Triclosan in Swedish Mothers and Their Children. Environ. Int. 2014, 73, 323–333. [CrossRef]eng
dcterms.referencesLee, Y.-M.; Kim, K.-S.; Jacobs, D.R.; Lee, D.-H. Persistent Organic Pollutants in Adipose Tissue Should Be Considered in Obesity Research. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2017, 18, 129–139. [CrossRef]eng
dcterms.referencesShin, M.-Y.; Shin, C.; Choi, J.W.; Lee, J.; Lee, S.; Kim, S. Pharmacokinetic Profile of Propyl Paraben in Humans after Oral Administration. Environ. Int. 2019, 130, 104917. [CrossRef]eng
dcterms.referencesNicolucci, C.; Errico, S.; Federico, A.; Dallio, M.; Loguercio, C.; Diano, N. Human Exposure to Bisphenol A and Liver Health Status: Quantification of Urinary and Circulating Levels by LC–MS/MS. J. Pharm. Biomed. Anal. 2017, 140, 105–112. [CrossRef]eng
dcterms.referencesUlasoglu, C.; Enc, F.Y.; Kaya, E.; Yilmaz, Y. Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. J. Gastrointestin. Liver Dis. 2019, 28, 427–431. [CrossRef]eng
dcterms.referencesKang, Y.; Park, S.; Kim, S.; Koh, H. Normal Serum Alanine Aminotransferase and Non-Alcoholic Fatty Liver Disease among Korean Adolescents: A Cross-Sectional Study Using Data from KNHANES 2010–2015. BMC Pediatr. 2018, 18, 215. [CrossRef] [PubMed]eng
dcterms.referencesKumar, J.; Lind, L.; Salihovic, S.; van Bavel, B.; Ingelsson, E.; Lind, P.M. Persistent Organic Pollutants and Liver Dysfunction Biomarkers in a Population-Based Human Sample of Men and Women. Environ. Res. 2014, 134, 251–256. [CrossRef] [PubMed]eng
dcterms.referencesBarali´c, K.; Buha Djordjevic, A.; Živanˇcevi´c, K.; Antonijevi´c, E.; Andelkovi´c, M.; Javorac, D.; ¯ Curˇci´c, M.; Bulat, Z.; Antonijevi´c, B.; ´ Ðuki´c-Cosi´c, D. Toxic Effects of the Mixture of Phthalates and Bisphenol A-Subacute Oral Toxicity Study in Wistar Rats. ´ Int. J. Environ. Res. Public Health 2020, 17, 746. [CrossRef]eng
dcterms.referencesHeindel, J.J.; Blumberg, B.; Cave, M.; Machtinger, R.; Mantovani, A.; Mendez, M.A.; Nadal, A.; Palanza, P.; Panzica, G.; Sargis, R.; et al. Metabolism Disrupting Chemicals and Metabolic Disorders. Reprod. Toxicol. Elmsford N 2017, 68, 3–33. [CrossRef] [PubMed]eng
dcterms.referencesLim, S.; Ahn, S.Y.; Song, I.C.; Chung, M.H.; Jang, H.C.; Park, K.S.; Lee, K.-U.; Pak, Y.K.; Lee, H.K. Chronic Exposure to the Herbicide, Atrazine, Causes Mitochondrial Dysfunction and Insulin Resistance. PLoS ONE 2009, 4, e5186. [CrossRef]eng
dcterms.referencesJin, Y.; Lin, X.; Miao, W.; Wu, T.; Shen, H.; Chen, S.; Li, Y.; Pan, Q.; Fu, Z. Chronic Exposure of Mice to Environmental Endocrine-Disrupting Chemicals Disturbs Their Energy Metabolism. Toxicol. Lett. 2014, 225, 392–400. [CrossRef]eng
dcterms.referencesAl-Eryani, L.; Wahlang, B.; Falkner, K.C.; Guardiola, J.J.; Clair, H.B.; Prough, R.A.; Cave, M. Identification of Environmental Chemicals Associated with the Development of Toxicant-Associated Fatty Liver Disease in Rodents. Toxicol. Pathol. 2015, 43, 482–497. [CrossRef] [PubMed]eng
dcterms.referencesMaradonna, F.; Carnevali, O. Lipid Metabolism Alteration by Endocrine Disruptors in Animal Models: An Overview. Front. Endocrinol. 2018, 9, 654. [CrossRef]eng
dcterms.referencesArmstrong, L.E.; Guo, G.L. Understanding Environmental Contaminants’ Direct Effects on Non-Alcoholic Fatty Liver Disease Progression. Curr. Environ. Health Rep. 2019, 6, 95–104. [CrossRef]eng
dcterms.referencesKawano, Y.; Cohen, D.E. Mechanisms of Hepatic Triglyceride Accumulation in Non-Alcoholic Fatty Liver Disease. J. Gastroenterol. 2013, 48, 434–441. [CrossRef]eng
dcterms.referencesIpsen, D.H.; Lykkesfeldt, J.; Tveden-Nyborg, P. Molecular Mechanisms of Hepatic Lipid Accumulation in Non-Alcoholic Fatty Liver Disease. Cell. Mol. Life Sci. CMLS 2018, 75, 3313–3327. [CrossRef]eng
dcterms.referencesGeisler, C.E.; Renquist, B.J. Hepatic Lipid Accumulation: Cause and Consequence of Dysregulated Glucoregulatory Hormones. J. Endocrinol. 2017, 234, R1–R21. [CrossRef]eng
dcterms.referencesPolyzos, S.A.; Kountouras, J.; Deretzi, G.; Zavos, C.; Mantzoros, C.S. The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease. Curr. Mol. Med. 2012, 12, 68–82. [CrossRef] [PubMed]eng
dcterms.referencesWahlang, B.; Hardesty, J.E.; Jin, J.; Falkner, K.C.; Cave, M.C. Polychlorinated Biphenyls and Nonalcoholic Fatty Liver Disease. Curr. Opin. Toxicol. 2019, 14, 21–28. [CrossRef]eng
dcterms.referencesShan, Q.; Chen, N.; Liu, W.; Qu, F.; Chen, A. Exposure to 2,3,30 ,4,40 ,5-Hexachlorobiphenyl Promotes Nonalcoholic Fatty Liver Disease Development in C57BL/6 Mice. Environ. Pollut. 2020, 263, 114563. [CrossRef] [PubMed]eng
dcterms.referencesWan, H.T.; Zhao, Y.G.; Wei, X.; Hui, K.Y.; Giesy, J.P.; Wong, C.K.C. PFOS-Induced Hepatic Steatosis, the Mechanistic Actions on β-Oxidation and Lipid Transport. Biochim. Biophys. Acta BBA Gen. Subj. 2012, 1820, 1092–1101. [CrossRef] [PubMed]eng
dcterms.referencesDas, K.P.; Wood, C.R.; Lin, M.T.; Starkov, A.A.; Lau, C.; Wallace, K.B.; Corton, J.C.; Abbott, B.D. Perfluoroalkyl Acids-Induced Liver Steatosis: Effects on Genes Controlling Lipid Homeostasis. Toxicology 2017, 378, 37–52. [CrossRef]eng
dcterms.referencesYan, S.; Wang, J.; Dai, J. Activation of Sterol Regulatory Element-Binding Proteins in Mice Exposed to Perfluorooctanoic Acid for 28 Days. Arch. Toxicol. 2015, 89, 1569–1578. [CrossRef] [PubMed]eng
dcterms.referencesZhang, H.; He, J.; Li, N.; Gao, N.; Du, Q.; Chen, B.; Chen, F.; Shan, X.; Ding, Y.; Zhu, W.; et al. Lipid Accumulation Responses in the Liver of Rana Nigromaculata Induced by Perfluorooctanoic Acid (PFOA). Ecotoxicol. Environ. Saf. 2019, 167, 29–35. [CrossRef]eng
dcterms.referencesChen, H.; Zhang, W.; Rui, B.; Yang, S.; Xu, W.; Wei, W. Di(2-Ethylhexyl) Phthalate Exacerbates Non-Alcoholic Fatty Liver in Rats and Its Potential Mechanisms. Environ. Toxicol. Pharmacol. 2016, 42, 38–44. [CrossRef]eng
dcterms.referencesZhang, Y.; Wang, S.; Zhao, T.; Yang, L.; Guo, S.; Shi, Y.; Zhang, X.; Zhou, L.; Ye, L. Mono-2-Ethylhexyl Phthalate (MEHP) Promoted Lipid Accumulation via JAK2/STAT5 and Aggravated Oxidative Stress in BRL-3A Cells. Ecotoxicol. Environ. Saf. 2019, 184, 109611. [CrossRef]eng
dcterms.referencesBai, J.; He, Z.; Li, Y.; Jiang, X.; Yu, H.; Tan, Q. Mono-2-Ethylhexyl Phthalate Induces the Expression of Genes Involved in Fatty Acid Synthesis in HepG2 Cells. Environ. Toxicol. Pharmacol. 2019, 69, 104–111. [CrossRef]eng
dcterms.referencesDallio, M.; Diano, N.; Masarone, M.; Gravina, A.G.; Patanè, V.; Romeo, M.; Di Sarno, R.; Errico, S.; Nicolucci, C.; Abenavoli, L.; et al. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. Int. J. Environ. Res. Public Health 2019, 16, 3134. [CrossRef] [PubMed]eng
dcterms.referencesMarmugi, A.; Ducheix, S.; Lasserre, F.; Polizzi, A.; Paris, A.; Priymenko, N.; Bertrand-Michel, J.; Pineau, T.; Guillou, H.; Martin, P.G.P.; et al. Low Doses of Bisphenol A Induce Gene Expression Related to Lipid Synthesis and Trigger Triglyceride Accumulation in Adult Mouse Liver. Hepatol. Baltim. Md 2012, 55, 395–407. [CrossRef] [PubMed]eng
dcterms.referencesMartella, A.; Silvestri, C.; Maradonna, F.; Gioacchini, G.; Allarà, M.; Radaelli, G.; Overby, D.R.; Di Marzo, V.; Carnevali, O. Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop. Endocrinology 2016, 157, 1751–1763. [CrossRef] [PubMed]eng
dcterms.referencesWei, Y.; Rector, R.S.; Thyfault, J.P.; Ibdah, J.A. Nonalcoholic Fatty Liver Disease and Mitochondrial Dysfunction. World J. Gastroenterol. 2008, 14, 193–199. [CrossRef] [PubMed]eng
dcterms.referencesEiner, C.; Hohenester, S.; Wimmer, R.; Wottke, L.; Artmann, R.; Schulz, S.; Gosmann, C.; Simmons, A.; Leitzinger, C.; Eberhagen, C.; et al. Mitochondrial Adaptation in Steatotic Mice. Mitochondrion 2018, 40, 1–12. [CrossRef]eng
dcterms.referencesSimões, I.C.M.; Fontes, A.; Pinton, P.; Zischka, H.; Wieckowski, M.R. Mitochondria in Non-Alcoholic Fatty Liver Disease. Int. J. Biochem. Cell Biol. 2018, 95, 93–99. [CrossRef] [PubMed]eng
dcterms.referencesMansouri, A.; Gattolliat, C.-H.; Asselah, T. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology 2018, 155, 629–647. [CrossRef] [PubMed]eng
dcterms.referencesMarroqui, L.; Tudurí, E.; Alonso-Magdalena, P.; Quesada, I.; Nadal, Á.; Dos Santos, R.S. Mitochondria as Target of EndocrineDisrupting Chemicals: Implications for Type 2 Diabetes. J. Endocrinol. 2018, 239, R27–R45. [CrossRef]eng
dcterms.referencesLim, S.; Cho, Y.M.; Park, K.S.; Lee, H.K. Persistent Organic Pollutants, Mitochondrial Dysfunction, and Metabolic Syndrome. Ann. N. Y. Acad. Sci. 2010, 1201, 166–176. [CrossRef] [PubMed]eng
dcterms.referencesSagarkar, S.; Gandhi, D.; Devi, S.S.; Sakharkar, A.; Kapley, A. Atrazine Exposure Causes Mitochondrial Toxicity in Liver and Muscle Cell Lines. Indian J. Pharmacol. 2016, 48, 200–207. [CrossRef] [PubMed]eng
dcterms.referencesKhan, S.; Beigh, S.; Chaudhari, B.P.; Sharma, S.; Aliul Hasan Abdi, S.; Ahmad, S.; Ahmad, F.; Parvez, S.; Raisuddin, S. Mitochondrial Dysfunction Induced by Bisphenol A Is a Factor of Its Hepatotoxicity in Rats. Environ. Toxicol. 2016, 31, 1922–1934. [CrossRef]eng
dcterms.referencesJiang, Y.; Xia, W.; Zhu, Y.; Li, X.; Wang, D.; Liu, J.; Chang, H.; Li, G.; Xu, B.; Chen, X.; et al. Mitochondrial Dysfunction in Early Life Resulted from Perinatal Bisphenol A Exposure Contributes to Hepatic Steatosis in Rat Offspring. Toxicol. Lett. 2014, 228, 85–92. [CrossRef]eng
dcterms.referencesYu, J.; Yang, X.; Yang, X.; Yang, M.; Wang, P.; Yang, Y.; Yang, J.; Li, W.; Xu, J. Nonylphenol Aggravates Non-Alcoholic Fatty Liver Disease in High Sucrose-High Fat Diet-Treated Rats. Sci. Rep. 2018, 8, 3232. [CrossRef] [PubMed]eng
dcterms.referencesKourouma, A.; Keita, H.; Duan, P.; Quan, C.; Bilivogui, K.K.; Qi, S.; Christiane, N.A.; Osamuyimen, A.; Yang, K. Effects of 4-Nonylphenol on Oxidant/Antioxidant Balance System Inducing Hepatic Steatosis in Male Rat. Toxicol. Rep. 2015, 2, 1423–1433. [CrossRef]eng
dcterms.referencesHe, X.; Gao, J.; Hou, H.; Qi, Z.; Chen, H.; Zhang, X.-X. Inhibition of Mitochondrial Fatty Acid Oxidation Contributes to Development of Nonalcoholic Fatty Liver Disease Induced by Environmental Cadmium Exposure. Environ. Sci. Technol. 2019, 53, 13992–14000. [CrossRef] [PubMed]eng
dcterms.referencesDing, R.-B.; Bao, J.; Deng, C.-X. Emerging Roles of SIRT1 in Fatty Liver Diseases. Int. J. Biol. Sci. 2017, 13, 852–867. [CrossRef] [PubMed]eng
dcterms.referencesBanks, A.S.; Kon, N.; Knight, C.; Matsumoto, M.; Gutiérrez-Juárez, R.; Rossetti, L.; Gu, W.; Accili, D. SirT1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in Mice. Cell Metab. 2008, 8, 333–341. [CrossRef] [PubMed]eng
dcterms.referencesWang, H.; Qiang, L.; Farmer, S.R. Identification of a Domain within Peroxisome Proliferator-Activated Receptor γ Regulating Expression of a Group of Genes Containing Fibroblast Growth Factor 21 That Are Selectively Repressed by SIRT1 in Adipocytes. Mol. Cell. Biol. 2008, 28, 188–200. [CrossRef]eng
dcterms.referencesMilne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; et al. Small Molecule Activators of SIRT1 as Therapeutics for the Treatment of Type 2 Diabetes. Nature 2007, 450, 712–716. [CrossRef]eng
dcterms.referencesLi, X.; Zhang, S.; Blander, G.; Tse, J.G.; Krieger, M.; Guarente, L. SIRT1 Deacetylates and Positively Regulates the Nuclear Receptor LXR. Mol. Cell 2007, 28, 91–106. [CrossRef] [PubMed]eng
dcterms.referencesWang, L.; Sun, M.; Cao, Y.; Ma, L.; Shen, Y.; Velikanova, A.A.; Li, X.; Sun, C.; Zhao, Y. MiR-34a Regulates Lipid Metabolism by Targeting SIRT1 in Non-Alcoholic Fatty Liver Disease with Iron Overload. Arch. Biochem. Biophys. 2020, 695, 108642. [CrossRef]eng
dcterms.referencesYoshizaki, T.; Milne, J.C.; Imamura, T.; Schenk, S.; Sonoda, N.; Babendure, J.L.; Lu, J.-C.; Smith, J.J.; Jirousek, M.R.; Olefsky, J.M. SIRT1 Exerts Anti-Inflammatory Effects and Improves Insulin Sensitivity in Adipocytes. Mol. Cell. Biol. 2009, 29, 1363–1374. [CrossRef]eng
dcterms.referencesYamazaki, Y.; Usui, I.; Kanatani, Y.; Matsuya, Y.; Tsuneyama, K.; Fujisaka, S.; Bukhari, A.; Suzuki, H.; Senda, S.; Imanishi, S.; et al. Treatment with SRT1720, a SIRT1 Activator, Ameliorates Fatty Liver with Reduced Expression of Lipogenic Enzymes in MSG Mice. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E1179–E1186. [CrossRef]eng
dcterms.referencesColak, Y.; Ozturk, O.; Senates, E.; Tuncer, I.; Yorulmaz, E.; Adali, G.; Doganay, L.; Enc, F.Y. SIRT1 as a Potential Therapeutic Target for Treatment of Nonalcoholic Fatty Liver Disease. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2011, 17, HY5–HY9. [CrossRef]eng
dcterms.referencesBai, P.; Cantó, C.; Oudart, H.; Brunyánszki, A.; Cen, Y.; Thomas, C.; Yamamoto, H.; Huber, A.; Kiss, B.; Houtkooper, R.H.; et al. PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation. Cell Metab. 2011, 13, 461–468. [CrossRef]eng
dcterms.references. Peverill, W.; Powell, L.W.; Skoien, R. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. Int. J. Mol. Sci. 2014, 15, 8591–8638. [CrossRef]eng
dcterms.referencesLuedde, T.; Schwabe, R.F. NF-KB in the Liver–Linking Injury, Fibrosis and Hepatocellular Carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 108–118. [CrossRef] [PubMed]eng
dcterms.referencesHuc, L.; Lemarié, A.; Guéraud, F.; Héliès-Toussaint, C. Low Concentrations of Bisphenol A Induce Lipid Accumulation Mediated by the Production of Reactive Oxygen Species in the Mitochondria of HepG2 Cells. Toxicol. Vitro Int. J. Publ. Assoc. BIBRA 2012, 26, 709–717. [CrossRef] [PubMed]eng
dcterms.referencesHan, R.; Hu, M.; Zhong, Q.; Wan, C.; Liu, L.; Li, F.; Zhang, F.; Ding, W. Perfluorooctane Sulphonate Induces Oxidative Hepatic Damage via Mitochondria-Dependent and NF-KB/TNF-α-Mediated Pathway. Chemosphere 2018, 191, 1056–1064. [CrossRef] [PubMed]eng
dcterms.referencesDeng, P.; Barney, J.; Petriello, M.C.; Morris, A.J.; Wahlang, B.; Hennig, B. Hepatic Metabolomics Reveals That Liver Injury Increases PCB 126-Induced Oxidative Stress and Metabolic Dysfunction. Chemosphere 2019, 217, 140–149. [CrossRef] [PubMed]eng
dcterms.referencesPark, C.G.; Sung, B.; Ryu, C.S.; Kim, Y.J. Mono-(2-Ethylhexyl) Phthalate Induces Oxidative Stress and Lipid Accumulation in Zebrafish Liver Cells. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2020, 230, 108704. [CrossRef] [PubMed]eng
dcterms.referencesArrese, M.; Cabrera, D.; Kalergis, A.M.; Feldstein, A.E. Innate Immunity and Inflammation in NAFLD/NASH. Dig. Dis. Sci. 2016, 61, 1294–1303. [CrossRef]eng
dcterms.referencesSchuster, S.; Cabrera, D.; Arrese, M.; Feldstein, A.E. Triggering and Resolution of Inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 2018, 15, 349–364. [CrossRef]eng
dcterms.referencesAlisi, A.; Carpino, G.; Oliveira, F.L.; Panera, N.; Nobili, V.; Gaudio, E. The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. Mediat. Inflamm. 2017, 2017, 8162421. [CrossRef] [PubMed]eng
dcterms.referencesKatsarou, A.; Moustakas, I.I.; Pyrina, I.; Lembessis, P.; Koutsilieris, M.; Chatzigeorgiou, A. Metabolic Inflammation as an Instigator of Fibrosis during Non-Alcoholic Fatty Liver Disease. World J. Gastroenterol. 2020, 26, 1993–2011. [CrossRef]eng
dcterms.referencesMeyer, S.K.; Probert, P.M.E.; Lakey, A.F.; Axon, A.R.; Leitch, A.C.; Williams, F.M.; Jowsey, P.A.; Blain, P.G.; Kass, G.E.N.; Wright, M.C. Hepatic Effects of Tartrazine (E 102) after Systemic Exposure Are Independent of Oestrogen Receptor Interactions in the Mouse. Toxicol. Lett. 2017, 273, 55–68. [CrossRef]eng
dcterms.referencesAcaroz, U.; Ince, S.; Arslan-Acaroz, D.; Gurler, Z.; Demirel, H.H.; Kucukkurt, I.; Eryavuz, A.; Kara, R.; Varol, N.; Zhu, K. Bisphenol-A Induced Oxidative Stress, Inflammatory Gene Expression, and Metabolic and Histopathological Changes in Male Wistar Albino Rats: Protective Role of Boron. Toxicol. Res. 2019, 8, 262–269. [CrossRef]eng
dcterms.referencesLv, Q.; Gao, R.; Peng, C.; Yi, J.; Liu, L.; Yang, S.; Li, D.; Hu, J.; Luo, T.; Mei, M.; et al. Bisphenol A Promotes Hepatic Lipid Deposition Involving Kupffer Cells M1 Polarization in Male Mice. J. Endocrinol. 2017, 234, 143–154. [CrossRef]eng
dcterms.referencesHan, R.; Zhang, F.; Wan, C.; Liu, L.; Zhong, Q.; Ding, W. Effect of Perfluorooctane Sulphonate-Induced Kupffer Cell Activation on Hepatocyte Proliferation through the NF-KB/TNF-α/IL-6-Dependent Pathway. Chemosphere 2018, 200, 283–294. [CrossRef] [PubMed]eng
dcterms.referencesZhao, Z.-B.; Ji, K.; Shen, X.-Y.; Zhang, W.-W.; Wang, R.; Xu, W.-P.; Wei, W. Di(2-Ethylhexyl) Phthalate Promotes Hepatic Fibrosis by Regulation of Oxidative Stress and Inflammation Responses in Rats. Environ. Toxicol. Pharmacol. 2019, 68, 109–119. [CrossRef] [PubMed]eng
dcterms.referencesGaitantzi, H.; Hakenberg, P.; Theobald, J.; Heinlein, H.; Cai, C.; Loff, S.; Wölfl, S.; Ebert, M.P.; Breitkopf-Heinlein, K.; Subotic, U. Di (2-Ethylhexyl) Phthalate and Its Role in Developing Cholestasis: An In Vitro Study on Different Liver Cell Types. J. Pediatr. Gastroenterol. Nutr. 2018, 66, e28–e35. [CrossRef] [PubMed]eng
dcterms.referencesLee, C.-Y.; Suk, F.-M.; Twu, Y.-C.; Liao, Y.-J. Long-Term Exposure to Low-Dose Di-(2-Ethylhexyl) Phthalate Impairs Cholesterol Metabolism in Hepatic Stellate Cells and Exacerbates Liver Librosis. Int. J. Environ. Res. Public Health 2020, 17, 3802. [CrossRef] [PubMed]eng
dcterms.referencesHarvey, W.A.; Jurgensen, K.; Pu, X.; Lamb, C.L.; Cornell, K.A.; Clark, R.J.; Klocke, C.; Mitchell, K.A. Exposure to 2,3,7,8- Tetrachlorodibenzo-p-Dioxin (TCDD) Increases Human Hepatic Stellate Cell Activation. Toxicology 2016, 344–346, 26–33. [CrossRef]eng
dcterms.referencesDoskey, C.M.; Fader, K.A.; Nault, R.; Lydic, T.; Matthews, J.; Potter, D.; Sharratt, B.; Williams, K.; Zacharewski, T. 2,3,7,8- Tetrachlorodibenzo-p-Dioxin (TCDD) Alters Hepatic Polyunsaturated Fatty Acid Metabolism and Eicosanoid Biosynthesis in Female Sprague-Dawley Rats. Toxicol. Appl. Pharmacol. 2020, 398, 115034. [CrossRef] [PubMed]eng
dcterms.referencesFoulds, C.E.; Treviño, L.S.; York, B.; Walker, C.L. Endocrine-Disrupting Chemicals and Fatty Liver Disease. Nat. Rev. Endocrinol. 2017, 13, 445–457. [CrossRef] [PubMed]eng
dcterms.referencesWalker, C.L. Minireview: Epigenomic Plasticity and Vulnerability to EDC Exposures. Mol. Endocrinol. Baltim. Md. 2016, 30, 848–855. [CrossRef] [PubMed]eng
dcterms.referencesTreviño, L.S.; Dong, J.; Kaushal, A.; Katz, T.A.; Jangid, R.K.; Robertson, M.J.; Grimm, S.L.; Ambati, C.S.R.; Putluri, V.; Cox, A.R.; et al. Epigenome Environment Interactions Accelerate Epigenomic Aging and Unlock Metabolically Restricted Epigenetic Reprogramming in Adulthood. Nat. Commun. 2020, 11, 2316. [CrossRef]eng
dcterms.referencesSkinner, M.K.; Manikkam, M.; Guerrero-Bosagna, C. Epigenetic Transgenerational Actions of Environmental Factors in Disease Etiology. Trends Endocrinol. Metab. TEM 2010, 21, 214–222. [CrossRef]eng
dcterms.referencesRissman, E.F.; Adli, M. Minireview: Transgenerational Epigenetic Inheritance: Focus on Endocrine Disrupting Compounds. Endocrinology 2014, 155, 2770–2780. [CrossRef] [PubMed]eng
dcterms.referencesSkinner, M.K. What Is an Epigenetic Transgenerational Phenotype? F3 or F2. Reprod. Toxicol. Elmsford N 2008, 25, 2–6. [CrossRef]eng
dcterms.referencesPatterson, T.A.; Twaddle, N.C.; Roegge, C.S.; Callicott, R.J.; Fisher, J.W.; Doerge, D.R. Concurrent Determination of Bisphenol A Pharmacokinetics in Maternal and Fetal Rhesus Monkeys. Toxicol. Appl. Pharmacol. 2013, 267, 41–48. [CrossRef]eng
dcterms.referencesDolinoy, D.C.; Huang, D.; Jirtle, R.L. Maternal Nutrient Supplementation Counteracts Bisphenol A-Induced DNA Hypomethylation in Early Development. Proc. Natl. Acad. Sci. USA 2007, 104, 13056–13061. [CrossRef] [PubMed]eng
dcterms.referencesDoshi, T.; Mehta, S.S.; Dighe, V.; Balasinor, N.; Vanage, G. Hypermethylation of Estrogen Receptor Promoter Region in Adult Testis of Rats Exposed Neonatally to Bisphenol A. Toxicology 2011, 289, 74–82. [CrossRef]eng
dcterms.referencesZhu, L.; Liu, Y.; Xue, X.; Yuan, C.; Wang, Z. BPA’s Transgenerational Disturbance to Transcription of Ovarian Steroidogenic Genes in Rare Minnow Gobiocypris Rarus via DNA and Histone Methylation. Sci. Total Environ. 2021, 762, 143055. [CrossRef]eng
dcterms.referencesQin, T.; Zhang, X.; Guo, T.; Yang, T.; Gao, Y.; Hao, W.; Xiao, X. Epigenetic Alteration Shaped by the Environmental Chemical Bisphenol A. Front. Genet. 2020, 11, 618966. [CrossRef] [PubMed]eng
dcterms.referencesLongo, M.; Zatterale, F.; Naderi, J.; Nigro, C.; Oriente, F.; Formisano, P.; Miele, C.; Beguinot, F. Low-Dose Bisphenol-A Promotes Epigenetic Changes at Pparγ Promoter in Adipose Precursor Cells. Nutrients 2020, 12, 3498. [CrossRef]eng
dcterms.referencesMcCabe, C.F.; Padmanabhan, V.; Dolinoy, D.C.; Domino, S.E.; Jones, T.R.; Bakulski, K.M.; Goodrich, J.M. Maternal Environmental Exposure to Bisphenols and Epigenome-Wide DNA Methylation in Infant Cord Blood. Environ. Epigenetics 2020, 6, dvaa021. [CrossRef]eng
dcterms.referencesCimmino, I.; Fiory, F.; Perruolo, G.; Miele, C.; Beguinot, F.; Formisano, P.; Oriente, F. Potential Mechanisms of Bisphenol A (BPA) Contributing to Human Disease. Int. J. Mol. Sci. 2020, 21, 5761. [CrossRef] [PubMed]eng
dcterms.referencesMa, Y.; Xia, W.; Wang, D.Q.; Wan, Y.J.; Xu, B.; Chen, X.; Li, Y.Y.; Xu, S.Q. Hepatic DNA Methylation Modifications in Early Development of Rats Resulting from Perinatal BPA Exposure Contribute to Insulin Resistance in Adulthood. Diabetologia 2013, 56, 2059–2067. [CrossRef]eng
dcterms.referencesKe, Z.-H.; Pan, J.-X.; Jin, L.-Y.; Xu, H.-Y.; Yu, T.-T.; Ullah, K.; Rahman, T.U.; Ren, J.; Cheng, Y.; Dong, X.-Y.; et al. Bisphenol A Exposure May Induce Hepatic Lipid Accumulation via Reprogramming the DNA Methylation Patterns of Genes Involved in Lipid Metabolism. Sci. Rep. 2016, 6, 31331. [CrossRef] [PubMed]eng
dcterms.referencesChen, H. Chronic Inorganic Arsenic Exposure Induces Hepatic Global and Individual Gene Hypomethylation: Implications for Arsenic Hepatocarcinogenesis. Carcinogenesis 2004, 25, 1779–1786. [CrossRef]eng
dcterms.referencesDitzel, E.J.; Nguyen, T.; Parker, P.; Camenisch, T.D. Effects of Arsenite Exposure during Fetal Development on Energy Metabolism and Susceptibility to Diet-Induced Fatty Liver Disease in Male Mice. Environ. Health Perspect. 2016, 124, 201–209. [CrossRef]eng
dcterms.referencesGu, H.; Liu, Y.; Wang, W.; Ding, L.; Teng, W.; Liu, L. In Utero Exposure to Di-(2-Ethylhexyl) Phthalate Induces Metabolic Disorder and Increases Fat Accumulation in Visceral Depots of C57BL/6J Mice Offspring. Exp. Ther. Med. 2016, 12, 3806–3812. [CrossRef]eng
dcterms.referencesManikkam, M.; Tracey, R.; Guerrero-Bosagna, C.; Skinner, M.K. Plastics Derived Endocrine Disruptors (BPA, DEHP and DBP) Induce Epigenetic Transgenerational Inheritance of Obesity, Reproductive Disease and Sperm Epimutations. PLoS ONE 2013, 8, e55387. [CrossRef]eng
dcterms.referencesKing, S.E.; McBirney, M.; Beck, D.; Sadler-Riggleman, I.; Nilsson, E.; Skinner, M.K. Sperm Epimutation Biomarkers of Obesity and Pathologies Following DDT Induced Epigenetic Transgenerational Inheritance of Disease. Environ. Epigenetics 2019, 5, dvz008. [CrossRef]eng
dcterms.referencesStrakovsky, R.S.; Wang, H.; Engeseth, N.J.; Flaws, J.A.; Helferich, W.G.; Pan, Y.-X.; Lezmi, S. Developmental Bisphenol A (BPA) Exposure Leads to Sex-Specific Modification of Hepatic Gene Expression and Epigenome at Birth That May Exacerbate High-Fat Diet-Induced Hepatic Steatosis. Toxicol. Appl. Pharmacol. 2015, 284, 101–112. [CrossRef]eng
dcterms.referencesMaranghi, F.; Lorenzetti, S.; Tassinari, R.; Moracci, G.; Tassinari, V.; Marcoccia, D.; Di Virgilio, A.; Eusepi, A.; Romeo, A.; Magrelli, A.; et al. In Utero Exposure to Di-(2-Ethylhexyl) Phthalate Affects Liver Morphology and Metabolism in Post-Natal CD-1 Mice. Reprod. Toxicol. Elmsford N 2010, 29, 427–432. [CrossRef]eng
dcterms.referencesChamorro-García, R.; Sahu, M.; Abbey, R.J.; Laude, J.; Pham, N.; Blumberg, B. Transgenerational Inheritance of Increased Fat Depot Size, Stem Cell Reprogramming, and Hepatic Steatosis Elicited by Prenatal Exposure to the Obesogen Tributyltin in Mice. Environ. Health Perspect. 2013, 121, 359–366. [CrossRef] [PubMed]eng
dcterms.referencesZuo, Z.; Chen, S.; Wu, T.; Zhang, J.; Su, Y.; Chen, Y.; Wang, C. Tributyltin Causes Obesity and Hepatic Steatosis in Male Mice. Environ. Toxicol. 2011, 26, 79–85. [CrossRef]eng
dcterms.referencesBoverhof, D.R.; Burgoon, L.D.; Tashiro, C.; Sharratt, B.; Chittim, B.; Harkema, J.R.; Mendrick, D.L.; Zacharewski, T.R. Comparative Toxicogenomic Analysis of the Hepatotoxic Effects of TCDD in Sprague Dawley Rats and C57BL/6 Mice. Toxicol. Sci. Off. J. Soc. Toxicol. 2006, 94, 398–416. [CrossRef]eng
dcterms.referencesTomaszewski, K.E.; Montgomery, C.A.; Melnick, R.L. Modulation of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Toxicity in F344 Rats by Di(2-Ethylhexyl)Phthalate. Chem. Biol. Interact. 1988, 65, 205–222. [CrossRef]eng
dcterms.referencesJones, G.; Greig, J.B. Pathological Changes in the Liver of Mice given 2,3,7,8-Tetrachlorodibenzo-p-Dioxin. Experientia 1975, 31, 1315–1317. [CrossRef] [PubMed]eng
dcterms.referencesRodríguez-Alcalá, L.M.; Sá, C.; Pimentel, L.L.; Pestana, D.; Teixeira, D.; Faria, A.; Calhau, C.; Gomes, A. Endocrine Disruptor DDE Associated with a High-Fat Diet Enhances the Impairment of Liver Fatty Acid Composition in Rats. J. Agric. Food Chem. 2015, 63, 9341–9348. [CrossRef]eng
dcterms.referencesTan, X.; Xie, G.; Sun, X.; Li, Q.; Zhong, W.; Qiao, P.; Sun, X.; Jia, W.; Zhou, Z. High Fat Diet Feeding Exaggerates Perfluorooctanoic Acid-Induced Liver Injury in Mice via Modulating Multiple Metabolic Pathways. PLoS ONE 2013, 8, e61409. [CrossRef] [PubMed]eng
dcterms.referencesLv, Z.; Li, G.; Li, Y.; Ying, C.; Chen, J.; Chen, T.; Wei, J.; Lin, Y.; Jiang, Y.; Wang, Y.; et al. Glucose and Lipid Homeostasis in Adult Rat Is Impaired by Early-Life Exposure to Perfluorooctane Sulfonate. Environ. Toxicol. 2013, 28, 532–542. [CrossRef]eng
dcterms.referencesCave, M.; Appana, S.; Patel, M.; Falkner, K.C.; McClain, C.J.; Brock, G. Polychlorinated Biphenyls, Lead, and Mercury Are Associated with Liver Disease in American Adults: NHANES 2003-2004. Environ. Health Perspect. 2010, 118, 1735–1742. [CrossRef]eng
dcterms.referencesKim, M.-J.; Marchand, P.; Henegar, C.; Antignac, J.-P.; Alili, R.; Poitou, C.; Bouillot, J.-L.; Basdevant, A.; Le Bizec, B.; Barouki, R.; et al. Fate and Complex Pathogenic Effects of Dioxins and Polychlorinated Biphenyls in Obese Subjects before and after Drastic Weight Loss. Environ. Health Perspect. 2011, 119, 377–383. [CrossRef]eng
dcterms.referencesPazderova-Vejlupková, J.; Lukás, E.; Nemcova, M.; P ˘ ícková, J.; Jirásek, L. The Development and Prognosis of Chronic Intoxication by Tetrachlordibenzo-p-Dioxin in Men. Arch. Environ. Health 1981, 36, 5–11. [CrossRef]eng
dcterms.referencesLee, C.-C.; Yao, Y.-J.; Chen, H.-L.; Guo, Y.-L.; Su, H.-J. Fatty Liver and Hepatic Function for Residents with Markedly High Serum PCDD/Fs Levels in Taiwan. J. Toxicol. Environ. Health A 2006, 69, 367–380. [CrossRef] [PubMed]eng
dcterms.referencesMocarelli, P.; Marocchi, A.; Brambilla, P.; Gerthoux, P.; Young, D.S.; Mantel, N. Clinical Laboratory Manifestations of Exposure to Dioxin in Children. A Six-Year Study of the Effects of an Environmental Disaster near Seveso, Italy. JAMA 1986, 256, 2687–2695. [CrossRef]eng
dcterms.referencesLin, C.-Y.; Lin, L.-Y.; Chiang, C.-K.; Wang, W.-J.; Su, Y.-N.; Hung, K.-Y.; Chen, P.-C. Investigation of the Associations between LowDose Serum Perfluorinated Chemicals and Liver Enzymes in US Adults. Am. J. Gastroenterol. 2010, 105, 1354–1363. [CrossRef] [PubMed]eng
dcterms.referencesGleason, J.A.; Post, G.B.; Fagliano, J.A. Associations of Perfluorinated Chemical Serum Concentrations and Biomarkers of Liver Function and Uric Acid in the US Population (NHANES), 2007-2010. Environ. Res. 2015, 136, 8–14. [CrossRef] [PubMed]eng
dcterms.referencesJin, R.; McConnell, R.; Catherine, C.; Xu, S.; Walker, D.I.; Stratakis, N.; Jones, D.P.; Miller, G.W.; Peng, C.; Conti, D.V.; et al. Perfluoroalkyl Substances and Severity of Nonalcoholic Fatty Liver in Children: An Untargeted Metabolomics Approach. Environ. Int. 2020, 134, 105220. [CrossRef] [PubMed]eng
dcterms.referencesLang, I.A.; Galloway, T.S.; Scarlett, A.; Henley, W.E.; Depledge, M.; Wallace, R.B.; Melzer, D. Association of Urinary Bisphenol A Concentration with Medical Disorders and Laboratory Abnormalities in Adults. JAMA 2008, 300, 1303–1310. [CrossRef] [PubMed]eng
dcterms.referencesLee, M.-R.; Park, H.; Bae, S.; Lim, Y.-H.; Kim, J.H.; Cho, S.-H.; Hong, Y.-C. Urinary Bisphenol A Concentrations Are Associated with Abnormal Liver Function in the Elderly: A Repeated Panel Study. J. Epidemiol. Community Health 2014, 68, 312–317. [CrossRef] [PubMed]eng
dcterms.referencesTarantino, G.; Valentino, R.; Di Somma, C.; D’Esposito, V.; Passaretti, F.; Pizza, G.; Brancato, V.; Orio, F.; Formisano, P.; Colao, A.; et al. Bisphenol A in Polycystic Ovary Syndrome and Its Association with Liver-Spleen Axis. Clin. Endocrinol. 2013, 78, 447–453. [CrossRef] [PubMed]eng
dcterms.referencesKhalil, N.; Ebert, J.R.; Wang, L.; Belcher, S.; Lee, M.; Czerwinski, S.A.; Kannan, K. Bisphenol A and Cardiometabolic Risk Factors in Obese Children. Sci. Total Environ. 2014, 470–471, 726–732. [CrossRef] [PubMed]eng
dcterms.referencesMedic-Stojanoska, M.; Milosevic, N.; Milanovic, M.; Stojanoski, S.; Vukovic, B.; Icin, T.; Bajkin, I.; Stepanovic, K.; Sudji, J.; Milic, N. Can Phthalates Impair Liver Function? Endocr. Abstr. 2019. [CrossRef]eng
dcterms.referencesMiloševi´c, N.; Mili´c, N.; Živanovi´c Bosi´c, D.; Bajkin, I.; Perˇci´c, I.; Abenavoli, L.; Medi´c Stojanoska, M. Potential Influence of the Phthalates on Normal Liver Function and Cardiometabolic Risk in Males. Environ. Monit. Assess. 2017, 190, 17. [CrossRef]eng
dcterms.referencesMotamed, N.; Sohrabi, M.; Ajdarkosh, H.; Hemmasi, G.; Maadi, M.; Sayeedian, F.S.; Pirzad, R.; Abedi, K.; Aghapour, S.; Fallahnezhad, M.; et al. Fatty Liver Index vs. Waist Circumference for Predicting Non-Alcoholic Fatty Liver Disease. World J. Gastroenterol. 2016, 22, 3023–3030. [CrossRef]eng
dcterms.referencesLee, S.B.; Kim, M.K.; Kang, S.; Park, K.; Kim, J.H.; Baik, S.J.; Nam, J.S.; Ahn, C.W.; Park, J.S. Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults. Endocrinol. Metab. Seoul Korea 2019, 34, 179–186. [CrossRef]eng
dcterms.referencesXu, C.; Ma, Z.; Wang, Y.; Liu, X.; Tao, L.; Zheng, D.; Guo, X.; Yang, X. Visceral Adiposity Index as a Predictor of NAFLD: A Prospective Study with 4-Year Follow-Up. Liver Int. Off. J. Int. Assoc. Study Liver 2018, 38, 2294–2300. [CrossRef]eng
dcterms.referencesÖzcabı, B.; Demirhan, S.; Akyol, M.; Öztürkmen Akay, H.; Güven, A. Lipid Accumulation Product Is a Predictor of Nonalcoholic Fatty Liver Disease in Childhood Obesity. Korean J. Pediatr. 2019, 62, 450–455. [CrossRef]eng
dcterms.referencesMansour-Ghanaei, R.; Mansour-Ghanaei, F.; Naghipour, M.; Joukar, F.; Atrkar-Roushan, Z.; Tabatabaii, M.; Ghorani, N. The Role of Anthropometric Indices in the Prediction of Non-Alcoholic Fatty Liver Disease in the PERSIAN Guilan Cohort Study (PGCS). J. Med. Life 2018, 11, 194–202. [CrossRef]eng
dcterms.referencesHatch, E.E.; Nelson, J.W.; Qureshi, M.M.; Weinberg, J.; Moore, L.L.; Singer, M.; Webster, T.F. Association of Urinary Phthalate Metabolite Concentrations with Body Mass Index and Waist Circumference: A Cross-Sectional Study of NHANES Data, 1999–2002. Environ. Health Glob. Access Sci. Source 2008, 7, 27. [CrossRef]eng
dcterms.referencesStahlhut, R.W.; van Wijngaarden, E.; Dye, T.D.; Cook, S.; Swan, S.H. Concentrations of Urinary Phthalate Metabolites Are Associated with Increased Waist Circumference and Insulin Resistance in Adult U.S. Males. Environ. Health Perspect. 2007, 115, 876–882. [CrossRef]eng
dcterms.referencesLee, D.-H.; Lee, I.-K.; Jin, S.-H.; Steffes, M.; Jacobs, D.R. Association between Serum Concentrations of Persistent Organic Pollutants and Insulin Resistance among Nondiabetic Adults: Results from the National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2007, 30, 622–628. [CrossRef] [PubMed]eng
dcterms.referencesLa Merrill, M.A.; Johnson, C.L.; Smith, M.T.; Kandula, N.R.; Macherone, A.; Pennell, K.D.; Kanaya, A.M. Exposure to Persistent Organic Pollutants (POPs) and Their Relationship to Hepatic Fat and Insulin Insensitivity among Asian Indian Immigrants in the United States. Environ. Sci. Technol. 2019, 53, 13906–13918. [CrossRef]eng
dcterms.referencesGeiger, S.D.; Yao, P.; Vaughn, M.G.; Qian, Z. PFAS Exposure and Overweight/Obesity among Children in a Nationally Representative Sample. Chemosphere 2021, 268, 128852. [CrossRef]eng
dcterms.references. Carter, D.; Dieterich, D.T.; Chang, C. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Clin. Liver Dis. 2018, 22, 213–227. [CrossRef] [PubMed]eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Role-of-Endocrine-Dirupting-Chemical.pdf
Tamaño:
1.24 MB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca